MCRB Stock Summary and Trading Ideas (Seres Therapeutics | NASDAQ:MCRB)

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics trades on the NASDAQ stock market under the symbol MCRB.

As of December 12, 2024, MCRB stock price declined to $0.86 with 1,026,787 million shares trading.

MCRB has a beta of 0.92, meaning it tends to be less sensitive to market movements. MCRB has a correlation of 0.01 to the broad based SPY ETF.

MCRB has a market cap of $146.92 million. This is considered a Micro Cap stock.

In the last 3 years, MCRB traded as high as $9.49 and as low as $.54.

The top ETF exchange traded funds that MCRB belongs to (by Net Assets): VTI, VXF, SCHA, VHT, QQQS.

MCRB has underperformed the market in the last year with a price return of -13.7% while the SPY ETF gained +32.3%. MCRB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.0% and -6.0%, respectively, while the SPY returned +9.3% and +0.9%, respectively.

MCRB support price is $.82 and resistance is $.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MCRB shares will trade within this expected range on the day.